Is the price fair?
What BRKR's price assumes
Today's price asks for 35% free cash flow growth a year; over the last three years Bruker Corporation delivered −30%, the price is ahead of the record.
1.59
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 0.59%
Free cash flow yield · Medical Devices median 4.0%
- Growth the price implies
- +35%
Growth the price implies · The price pays for +35% free cash flow growth a year for a decade; the business has delivered −30% a year over the last three.
- EV / sales
- 2.04
EV / sales
Details›
- EV / EBIToperating margin 1.4%: the multiple describes the denominator
- not meaningful
- EV / sales2026-Q1
- 2.04
- Free cash flow, trailing twelve months
- $51M
- Market capitalisation
- $8.71B
- 3-year revenue growth
- +9.7%
- 3-year free cash flow growth
- −30%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.